Readystate Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-8,800
Closed -$517K – 707
2024
Q1
$517K Buy
+8,800
New +$561K 0.01% 799

Other funds holding APLS

Readystate Asset Management's APLS Position: Q2 2026 in Review

Readystate Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 34,100 shares — an estimated $1.37M sold.

Readystate Asset Management first reported a position in APLS in Q1 2024 and held it in 4 quarters. The position peaked at $5.48M in Q3 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Readystate Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Readystate Asset Management sold 34,100 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.37M.
  • Readystate Asset Management first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Readystate Asset Management's Apellis Pharmaceuticals position peaked at $5.48M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Readystate Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.